Evidence map›Paper›PMID 35782999›Full record

ReviewSports medicine and health science2020

Sarcopenia: Clinical implications in ovarian cancer, diagnosis, etiology, and management.

Aeran Seol, Se Ik Kim, Yong Sang Song

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Sports medicine and health science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Aeran SeolDepartment of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Republic of Korea.
Se Ik KimDepartment of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Republic of Korea.
Yong Sang SongDepartment of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Republic of Korea.
Seoul National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sarcopenia, loss of skeletal muscle and function, is a common condition among the elderly and is known to cause adverse health outcomes and increased risk of morbidity and mortality. This progressive and generalized disorder imposes a considerable socioeconomic burden. Sarcopenia is observed commonly in cancer patients. As Asia is one of the fastest aging regions in the world, it is clear that incidences of both sarcopenia and ovarian cancer will increase together in Asian countries. Ovarian cancer patients are vulnerable to develop sarcopenia during the treatment course and progress of disease, and a considerable number of patients with ovarian cancer seems to have physical inactivity and sarcopenia already at the time of diagnosis. Therefore, management of sarcopenia should be conducted together in parallel with ovarian cancer treatment and surveillance. Thus, in this article, we will review the clinical importance of sarcopenia in the aspect of ovarian cancer. Definition of sarcopenia, diagnosis, etiology, and intervention will be also introduced.

Indexed as

ACEi, angiotensin converting enzyme inhibitorASM, appendicular skeletal muscle massAWGS, Asian Working Group for SarcopeniaBIA, bioelectrical impedance analysisBMI, body mass indexCINV, chemotherapy-induced nausea and vomitingCT, computed tomographyDefinitionDXA, dual-energy x-ray absorptiometryEMT, epithelial-to-mesenchymal transitionEWGSOP, European Working Group on Sarcopenia in Older PeopleGH, growth hormoneHMB, β-hydroxy-β-methylbutyrateHRT, hormone replacement therapyIGF-1, insulin like growth factor-1InterventionL3, the third lumbar vertebraMRI, magnetic resonance imagingNLR, neutrophil to lymphocyte ratioOECD, Organisation for Economic Co-operation and DevelopmentOS, overall survival the length of time from either the date of diagnosis or the start of treatment for a cancer that patients diagnosed with the disease are still aliveOvarian carcinomaPFS, progression-free survival the length of time during and after the treatment of cancer that a patient lives with the disease but it does not get worsePhysiologyPracticeRM, repetition maximumSarcopeniaSARM, selective androgen receptor modulatorSMM, skeletal muscle massSPPB, Short Physical Performance BatteryTUG, Timed-Up and Go

Identifiers

PMID35782999
PMCPMC9219260
OpenAlexW3093063004

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.